Axitinib Impurity 2(CAS: 1428728-83-9)

Axitinib Impurity 2 (CAS: 1428728-83-9) falls under the regulatory guidelines of the Chemical Abstracts Service (CAS) and is subject to regulations by authorities such as REACH in the European Union, TSCA in the United States, and the Globally Harmonized System of Classification and Labeling of Chemicals (GHS). Manufacturers and distributors should comply with safety data sheets (SDS) and hazardous material transport regulations.

In the synthesis of Axitinib Impurity 2 (CAS: 1428728-83-9), there are alternative reagents and pathways that can be used to avoid impurities. Common substitutes include using purer starting materials and more selective catalysts. Alternative synthetic routes may also be explored to minimize the formation of impurities.

The market for Axitinib Impurity 2 (CAS: 1428728-83-9) is closely tied to the broader market for Axitinib, a tyrosine kinase inhibitor used in the treatment of renal cell carcinoma. Research trends are focused on improving the efficacy and safety of Axitinib, which drives the need for high-quality impurity control. Market trends indicate a demand for more precise and efficient synthesis methods to ensure regulatory compliance and product quality.

Waste containing Axitinib Impurity 2 (CAS: 1428728-83-9) should be collected in appropriate containers and stored under controlled conditions to prevent degradation and contamination. The waste should be treated by incineration or other professional waste disposal methods to ensure compliance with environmental regulations. Proper precautions should be taken to minimize environmental impact and ensure safety during handling and disposal.